Depomed dumping hot flash drug Sefelsa after FDA rejection
This article was originally published in Scrip
Depomed President and CEO Jim Schoeneck said his company had pretty much accepted the likelihood the US FDA would reject Sefelsa (gabapentin 600mg) as a treatment for moderate-to-severe menopausal-related hot flashes and night sweats, a condition known as vasomotor symptoms (VMS), given the snub the firm got in March from the agency’s Advisory Committee for Reproductive Health Drugs (ACRHD).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.